Literature DB >> 27287783

Schizophrenia causes significant burden to patients' and caregivers' lives.

Monika Szkultecka-Dębek1, Katarzyna Miernik, Jarosław Stelmachowski, Miro Jakovljević, Vlado Jukić, Kaire Aadamsoo, Sven Janno, István Bitter, Judit Tolna, Marek Jarema, Slobodan Jankovic, Jan Pecenak, Livia Vavrusova, Rok Tavčar, Jacek Walczak, Darren Talbot, Joanna Augustyńska.   

Abstract

BACKGROUND: Schizophrenia is a serious public health problem and is ranked among the most disabling diseases in the world. The sub-study presented here was part of a larger project to characterize the burden of schizophrenia on healthcare systems and on individuals living with the disease in Central and Eastern Europe (CEE). AIMS: This sub-study aimed to assess and analyze the impact of schizophrenia on many aspects of the lives of patients and caregivers.
METHODS: Psychiatrists from selected centers in seven Central and Eastern European countries were asked to complete a questionnaire in order to collect information about the disease history, characteristics, treatment protocols and resources used for each randomly selected patient. All data were statistically analyzed and compared between countries.
RESULTS: Data from 961 patients with schizophrenia (mean age 40.7 years, 45.1% female) were included in the analysis. The mean number of days spent in hospital per patient per year across all seven countries was 25.3 days. Hospitalization occurred on average once per year, with psychiatrist visits 9.4 times per year. Of the patients in the study, 61% were single, 12% divorced and 22% married or cohabiting. Almost 84% were living with relatives or a partner; only 17% lived alone and, on average, 25% of patients received support from social workers. Relatives provided care for approximately 60% of patients and 4% of them had to stop working in order to do so. Twenty-nine percent of the patients were unemployed, and 56% received a disability pension or were retired, with only 19% in full-time employment or education.
CONCLUSION: Schizophrenia has a significant effect on the lives of patients and caregivers and impacts their social integration.

Entities:  

Mesh:

Year:  2016        PMID: 27287783

Source DB:  PubMed          Journal:  Psychiatr Danub        ISSN: 0353-5053            Impact factor:   1.063


  7 in total

1.  Cost-Effectiveness Evaluations of Psychological Therapies for Schizophrenia and Bipolar Disorder: A Systematic Review.

Authors:  Gemma Elizabeth Shields; Deborah Buck; Jamie Elvidge; Karen Petra Hayhurst; Linda Mary Davies
Journal:  Int J Technol Assess Health Care       Date:  2019-07-22       Impact factor: 2.188

2.  Modified Mediterranean Diet for Enrichment of Short Chain Fatty Acids: Potential Adjunctive Therapeutic to Target Immune and Metabolic Dysfunction in Schizophrenia?

Authors:  Jamie Joseph; Colin Depp; Pei-An B Shih; Kristen S Cadenhead; Geert Schmid-Schönbein
Journal:  Front Neurosci       Date:  2017-03-27       Impact factor: 4.677

3.  Effectiveness of aripiprazole once-monthly in schizophrenia patients pretreated with oral aripiprazole: a 6-month, real-life non-interventional study.

Authors:  Daniel Schöttle; Wolfgang Janetzky; Daniel Luedecke; Elmar Beck; Christoph U Correll; Klaus Wiedemann
Journal:  BMC Psychiatry       Date:  2018-11-14       Impact factor: 3.630

4.  Reduction of Involuntary Admissions in Patients With Severe Psychotic Disorders Treated in the ACCESS Integrated Care Model Including Therapeutic Assertive Community Treatment.

Authors:  Daniel Schöttle; Friederike Ruppelt; Benno G Schimmelmann; Anne Karow; Alexandra Bussopulos; Jürgen Gallinat; Klaus Wiedemann; Daniel Luedecke; Anja Christine Rohenkohl; Christian G Huber; Thomas Bock; Martin Lambert
Journal:  Front Psychiatry       Date:  2019-10-24       Impact factor: 4.157

5.  Double-Blinded Randomized Pilot Clinical Trial Comparing Cognitive Side Effects of Standard Ultra-Brief Right Unilateral ECT to 0.5 A Low Amplitude Seizure Therapy (LAP-ST).

Authors:  Nagy A Youssef; William V McCall; Dheeraj Ravilla; Laryssa McCloud; Peter B Rosenquist
Journal:  Brain Sci       Date:  2020-12-13

Review 6.  Assessment and Treatment of Negative Symptoms in Schizophrenia-A Regional Perspective.

Authors:  Istvan Bitter; Pavel Mohr; Natalia Raspopova; Agata Szulc; Jerzy Samochowiec; Ioana Valentina Micluia; Oleg Skugarevsky; Róbert Herold; Alma Mihaljevic-Peles; Nino Okribelashvili; Jozef Dragašek; Virginija Adomaitiene; Elmars Rancans; Jana Chihai; Natalia Maruta; Nadja P Marić; Vihra Milanova; Rok Tavčar; Sergey Mosolov
Journal:  Front Psychiatry       Date:  2022-02-04       Impact factor: 4.157

7.  A randomized Phase II trial evaluating efficacy, safety, and tolerability of oral BI 409306 in attenuated psychosis syndrome: Design and rationale.

Authors:  Richard S E Keefe; Scott W Woods; Tyrone D Cannon; Stephan Ruhrmann; Daniel H Mathalon; Philip McGuire; Holger Rosenbrock; Kristen Daniels; Daniel Cotton; Dooti Roy; Stephane Pollentier; Michael Sand
Journal:  Early Interv Psychiatry       Date:  2020-12-22       Impact factor: 2.732

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.